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Under conditions of obesity and insulin resistance,
the serine/threonine protein kinase Akt/PKB is re-
quired for lipid accumulation in liver. Two forkhead
transcription factors, FoxA2 and FoxO1, have been
suggested to function downstream of and to be
negatively regulated by Akt and are proposed as
key determinants of hepatic triglyceride content. In
this study, we utilize genetic loss of function experi-
ments to show that constitutive activation of neither
FoxA2 nor FoxO1 can account for the protection
from steatosis afforded by deletion of Akt2 in liver.
Rather, another downstream target positively regu-
latedbyAkt, themTORC1complex, is required in vivo
for de novo lipogenesis and Srebp1c expression.
Nonetheless, activation of mTORC1 and SREBP1c
is not sufficient to drive postprandial lipogenesis in
the absence of Akt2. These data show that insulin
signaling through Akt2 promotes anabolic lipid
metabolism independent of Foxa2 or FoxO1 and
through pathways additional to the mTORC1-depen-
dent activation of SREBP1c.
INTRODUCTION
Insulin is the primary hormone responsible for coordinating the
metabolic response to nutrient intake. Following a meal, insulin
suppresses the hepatic glucose production that provides the
brain substrate during fasting and directs ingested nutrients
into long-term energy stores. In particular, insulin promotes
triglyceride (TG) synthesis and storage utilizing dietary fatty acids
and induces de novo lipogenesis in liver and adipose tissue.
Much of this synchronized metabolic response is thought to be
mediated by hormone-dependent reduction in the transcription
of gluconeogenic genes, such as glucose-6-phosphotase,516 Cell Metabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Incatalytic subunit (G6pc), and cytosolic phosphoenolpyruvate
carboxykinase 1 (Pck1), and activation of lipogenic gene expres-
sion via the master regulator sterol regulatory element-binding
transcription factor 1c (Srebp1c) (Argaud et al., 1996; Horton
et al., 2002; O’Brien et al., 2001). Thus, the transcriptional targets
of the insulin signaling pathway are of considerable interest.
The serine/threonine kinase Akt (also known as protein kinase
B, PKB) is now well-established as a major mediator of the
metabolic actions of insulin (Whiteman et al., 2002). Akt2 is the
predominant isoform in the insulin-responsive tissues like liver,
muscle, and adipose tissue (Cho et al., 2001). Akt2 knockout
mice are ‘‘diabetic,’’ whereas liver-specific disruption of the
Akt2 gene has mild effects on glycemia but more dramatic
effects on lipogenic gene expression and steatosis in obese,
insulin-resistant mice (Cho et al., 2001; Leavens et al., 2009).
The canonical nuclear target of Akt, established in worms and
flies as well as vertebrates, is the transcription factor Foxhead
box O (FoxO) (Gross et al., 2009). Akt phosphorylates and
inhibits the transcriptional activity of FoxO at least in part by
promoting its exclusion from the nucleus (Durham et al., 1999;
Guo et al., 1999; Nakae et al., 1999; Rena et al., 1999; Tang
et al., 1999). There are now considerable data implicating
FoxO1 as an intermediate in the pathway by which insulin
through Akt suppresses hepatic gluconeogenic gene expression
and glucose output (Haeusler et al., 2010b; Li et al., 2007; Liu
et al., 2008; Matsumoto et al., 2007; Nakae et al., 2001; Puig-
server et al., 2003; Qu et al., 2006).
In contrast to the consensus of opinion regarding the role of
FoxO1 in the control of gluconeogenic gene expression, its
contribution to regulation of hepatic lipid metabolism remains
unclear. In some studies, expression of a constitutively active
FoxO1 in liver induces Srebp1c expression and hepatic TG ac-
cumulation, though others have not found this reponse; in addi-
tion, FoxO1 inhibits TG secretion (Matsumoto et al., 2006; Zhang
et al., 2006). In contrast, Kamagate et al. reported that FoxO1 is
necessary and sufficient to promote hepatic very-low-density
lipoprotein-associated TG (VLDL-TG) production and hypertri-
glyceridemia via its regulation ofmicrosomal TG transfer protein
(MTP), and further proposed that this pathway accounts forc.
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2008). Loss-of-function approaches to understand the contribu-
tion of FoxO1 to lipogenic gene expression have yielded few
striking results, though its ablation in streptozotocin (STZ)-
induced diabetes increases serum TG and VLDL-TG secretion
(Haeusler et al., 2010a). Deletion of Foxo1 in insulin receptor
substrate 1 and 2 (IRS1 and IRS2) double-knockout mouse livers
partially rescues the deficit in VLDL-TG secretion (Dong et al.,
2008). Ablation of all three FoxO isoforms in liver leads to hepatic
steatosis, potentially through regulating the expression of
nicotinamide phosphoribosyltransferase (Nampt) and conse-
quently NAD+ levels (Tao et al., 2011). Thus, there persists
considerable uncertainty concerning the physiological role of
FoxO1 in controlling hepatic lipid metabolism.
Another forkhead family transcription factor, FoxA2, has been
implicated in the control of hepatic lipid metabolism by insulin.
Like FoxO, FoxA2 is phosphorylated by Akt, thereby leading to
exclusion from the nucleus and inhibition of transcriptional
activity, though some investigators have found that FoxA2
resides in nuclei constitutively and does not respond to different
nutritional conditions (Wolfrum et al., 2004; Zhang et al., 2005).
Expression of a constitutively active FoxA2 in liver of obese
mice leads to a phenotype much like a deficiency of insulin sig-
naling, i.e., increased fatty acid oxidation and TG secretion and
reduced hepatic TG content (Wolfrum et al., 2004; Wolfrum
and Stoffel, 2006). However, the role of FoxA2 in insulin action
has been challenged; mice with liver-specific deletion of FoxA2
demonstrate impaired bile acid metabolism but no alterations
in hepatic or serum TG (Bochkis et al., 2008).
It has long been known that a major target of insulin signaling
in the regulation of hepatic lipid metabolism is another transcrip-
tion factor, SREBP1c, a member of the basic helix-loop-helix
leucine-zipper family (Ferre and Foufelle, 2010; Horton et al.,
2002). Both transcription and posttranslational processing of
SREBP1c to its transcriptionally active form are stimulated by
insulin signaling through Akt, contributing to postprandial
increases in de novo lipogenesis (Chakrabarti et al., 2010;
Fleischmann and Iynedjian, 2000; Leavens et al., 2009; Li et al.,
2010; Porstmann et al., 2005, 2008). SREBP1c translocates to
the Golgi complex where it is proteolyzed, liberating an amino-
terminal fragment that activates its own expression as well as
that of a set of lipogenic enzymes including fatty acid synthase
(Fasn), acetyl-Coenzyme A carboxylase (Acc), ATP citrate lyase
(Acly), and glycerol-3-phosphate acyltransferase (Gpat) (Horton
et al., 2002; Postic and Girard, 2008). Insulin’s ability to promote
Srebp1c expression depends on the mammalian target of
rapamycin complex 1 (mTORC1), as knockdown of an essential
component of mTORC1, Raptor (regulatory-associated protein
of mTOR), in multiple tissue culture cell lines significantly blunts
insulin or Akt-stimulated expression of Srebp1c and its targets
(Chakrabarti et al., 2010; Duvel et al., 2010; Porstmann et al.,
2008). In primary hepatocytes, rapamycin prevents the insulin-
dependent induction of Srebp1c, but not the reduction in Pck1,
consistent with the idea that distinct transcriptional targets
mediate the effect of insulin on gluconeogenic and lipogenic
gene expression (Li et al., 2010).
The goal of the experiments reported herein is to test the
dependency of these three transcriptional pathways as down-
stream targets linking insulin signaling to control of hepatic TGCellcontent and de novo lipogenesis in mice. We have taken a
genetic approach to address the epistatic relationship between
Akt and its downstream candidate nuclear targets. If inhibition
of FoxO1 or FoxA2 were critical to insulin signaling, then the
loss in hormone action that accompanies deletion of Akt2 in liver
would be reversed by concomitant deletion of the target tran-
scription factor. If Akt2 promotes de novo lipogenesis in liver
via mTORC1, both its activity and Srebp1c expression would
be decreased upon deletion of Akt2 in liver. Thus, we ablated
Akt2 expression in liver by tissue-specific homologous recombi-
nation alone or simultaneously with either FoxA2 or FoxO1, and
analyzed lipid metabolism. Neither FoxA2 nor FoxO1 is down-
stream of Akt2 in the control of hepatic lipid accumulation, but
rather FoxO1 reduces hepatic TG content upstream of or via
a parallel pathway to Akt2. We then tested the requirement
and sufficiency of activation of mTORC1 for de novo lipogenesis.
We found that mTORC1 was required for Srebp1c expression
and de novo lipogenesis, but, when hepatic Akt2 was deleted,
activation of mTORC1 and SREBP1c was insufficient to drive
de novo lipogenesis following a high-carbohydrate meal.
RESULTS
Akt2 Regulates Hepatic TG Accumulation Independent
of FoxA2
It has been proposed that insulin inhibits FoxA2 via Akt-depen-
dent phosphorylation and nuclear exclusion, controlling lipid
export, fatty acid oxidation, and accumulation of TG in the liver
(Wolfrum et al., 2004, 2008; Wolfrum and Stoffel, 2006). We
generated mice lacking both Akt2 and FoxA2 in liver by breeding
Akt2(loxP/loxP);FoxA2(loxP/loxP) mice to AFP-Cre, which is ex-
pressed exclusively in liver (Zhang et al., 2005). As shown in Fig-
ure 1A, we achieved essentially complete deletion of Akt2 in
both Akt2(loxP/loxP) and Akt2(loxP/loxP);FoxA2(loxP/loxP) mice. FoxA2
protein levels were also greatly reduced in both FoxA2 single-
knockout and Akt2, FoxA2 double-knockout hepatocytes (Fig-
ure 1A). Mice of all four genotypes were submitted to glucose
tolerance tests, which showed indistinguishable rates of glucose
disposal (see Figure S1A available online). In addition, there were
no significant changes in serum insulin or TG levels from either
fed or overnight-fasted mice lacking Akt2, FoxA2, or both in liver
(Figures S1B and S1C). Adipose tissue mass was the same
among the mice of all four genotypes (Figure S1D).
The TG content in livers deficient in Akt2, FoxA2, or both was
unchanged compared to wild-type controls when assayed in
mice under chow-fed conditions (Figure 1B). Akt2 is required
for accumulation of liver TG under some situations that induce
hepatic steatosis, and expression of a constitutively active
FoxA2 reduces hepatic TG accumulation in leptin-deficient
(ob/ob) mice (Leavens et al., 2009; Wolfrum et al., 2004; Wolfrum
and Stoffel, 2006). To address the question of whether endoge-
nous FoxA2 is responsible for the reduction in hepatic TG in livers
deficient in Akt2, mice lacking Akt2, FoxA2, or both in liver were
fed a high-fat diet (HFD) for 3 months. Glucose tolerance tests
were indistinguishable among the four genotypes (Figure S2A),
as were serum insulin and TG levels under both fasting and fed
conditions (Figures S2B and S2C). Loss of Akt2 in livers trended
to a decrease of hepatic TG accumulation relative to wild-type
controls after HFD feeding, and this was unaffected by deletionMetabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Inc. 517
Figure 2. Loss of Hepatic Akt2 Decreases TG Accumulation in Liver
Independent of FoxO1 under Normal Chow Feeding
(A) Deletion of Akt2 and FoxO1 in liver from wild-type controls (CON), AFP >
Cre;Akt2(loxP/loxP) (L-Akt2), AFP > Cre;Akt2(loxP/loxP) (L-FoxO1), and AFP > Cre;
Akt2(loxP/loxP);FoxO1(loxP/loxP) (L-Akt2:FoxO1) mice. Three male mice from each
group were sacrificed under fed conditions on normal chow, and liver lysates
were prepared to blot for Akt2, FoxO1, and b-actin (left). Real-time PCR was
performed on cDNA prepared from RNA from 2-month-old male mouse livers
under fed conditions, n = 3–5 for each genotype (right).
(B) Pyruvate tolerance test (PTT). Two-month-old male mice were fasted
overnight and then injected with 2 g/kg body weight pyruvate i.p. Blood
glucose was determined at 0, 15, 30, 60, and 120min after injection; n = 4–8 for
each genotype.
(C) Area under curve from PTT. The variance of AUC levels was significant
among four different genotypes by one-way ANOVA but did not achieve
statistical significance by pairwise comparison using Tukey’s post test.
(D) Hepatic TG levels from 2-month-old male mice fed normal chow after
overnight fasting; n = 5–7 for each genotype.
(E) Hepatic TG levels from fed, 2-month-old male mice on normal chow, n =
3–5 for each group. *p < 0.05, **p < 0.01 by one-way ANOVA followed by
Tukey’s post test; error bars represent SEM.
Figure 1. Akt2 Regulates Hepatic TG Accumulation Independent
of FoxA2
(A) Western blot detecting deletion of Akt2 and FoxA2 in primary hepato-
cytes isolated from wild-type controls (CON), AFP > Cre;Akt2(loxP/loxP)
(L-Akt2), AFP > Cre;FoxA2(loxP/loxP) (L-FoxA2), and AFP > Cre;Akt2(loxP/loxP);
FoxA2(loxP/loxP) (L-Akt2:FoxA2) mice. Two male mice for each genotype were
2 months old and under fed conditions when primary hepatocytes were iso-
lated.
(B) Hepatic TG levels under fed conditions on normal chow in 2-month-old
male mice, n = 8–10 for each genotype.
(C) Body weight (left) and hepatic TG levels (right) under fed conditions on
HFD. One-month-old male mice were subjected to 3 months of HFD feeding,
n = 6–7 for each genotype. The body weight of control mice of comparable age
but maintained on normal chow was 26.2 ± 0.4 g. The variance of hepatic TG
levels was significant among four different genotypes by one-way ANOVA but
did not achieve statistical significance upon pairwise comparison by Tukey’s
post test; error bars represent SEM.
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tions of diet-induced obesity (DIO), FoxA2 activity is unlikely to
be the cause of the protection from steatosis rendered by
removal of Akt2 from liver. These data are also consistent with
previous findings challenging the notion of FoxA2 as a target of
insulin signaling (Zhang et al., 2005).
Loss of Akt2 Suppresses Hepatic TG Levels
in FoxO1-Deficient Liver
FoxO1, a transcription factor negatively regulated by the insulin/
Akt signaling pathway, promotes expression of gluconeogenic
genes such as G6pc and Pck1 (Gross et al., 2009). To assess
the function of FoxO1 as a downstream target of Akt2, we
derived Akt2, FoxO1 and combined liver-specific double-
knockout mice. Akt2 and FoxO1 protein levels were significantly
reduced in Akt2 and FoxO1 single-knockout livers, respectively,
and in Akt2, FoxO1 double-knockout livers (Figure 2A, left),518 Cell Metabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Inand real-time PCR from either FoxO1 knockout livers or Akt2,
FoxO1 double-knockout livers showed reduction of FoxO1
mRNA levels compared to either wild-type controls or Akt2
knockout livers (Figure 2A, right). Under conditions of normal
chow feeding, both AFP > Cre;Akt2(loxP/loxP) and AFP > Cre;Fox-
O1(loxP/loxP) mice demonstrated normal glucose tolerance (Fig-
ure S3A). Moreover, serum insulin and TG levels were the
same for all four genotypes when assayed under either fasting
or fed conditions (Figures S3B and S3C). When challenged
with pyruvate, AFP > Cre;FoxO1(loxP/loxP) mice trended to lower
levels of blood glucose, as did AFP > Cre;Akt2(loxP/loxP);
FoxO1(loxP/loxP) mice. AFP > Cre;Akt2(loxP/loxP) mice did not differc.
Figure 3. Loss of Hepatic Akt2 Decreases TG
Accumulation in Liver Independent of FoxO1 under
HFD Feeding
(A) Glucose tolerance test (GTT). Four-month-old male
mice fed a HFD for 3 months were fasted overnight and
injected i.p. with 2 g/kg glucose (left). Area under curve
was taken from GTT (right); n = 4–5 for each genotype.
(B) Fasting and fed serum insulin levels; n = 4–5 for each
genotype.
(C) Fasting and fed serum TG levels; n = 4–5 for each
genotype.
(D) Body weight (left) and hepatic TG levels (right) under
fed conditions on HFD; n = 4–6. Body weight from control
mice that were of comparable age but maintained on
normal chow was 31.5 ± 1.3 g. The variance of hepatic TG
levels was significant among four different genotypes by
one-way ANOVA. *p < 0.05 by one-way ANOVA followed
by Tukey’s post test; error bars represent
SEM. Abbreviations are as indicated in Figure 2.
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consistent with previously published results that support amodel
in which FoxO1 regulates glucose output and is downstream of
Akt (Matsumoto et al., 2007).
After an overnight fast, AFP > Cre;Akt2(loxP/loxP), AFP > Cre;
FoxO1(loxP/loxP) and AFP > Cre;Akt2(loxP/loxP);FoxO1(loxP/loxP) mice
had hepatic TG levels indistinguishable from that in wild-type
controls (Leavens et al., 2009; Matsumoto et al., 2007)
(Figure 2D). Fed AFP > Cre;FoxO1(loxP/loxP) mice displayed
increased hepatic TG levels compared to controls and AFP >
Cre;Akt2(loxP/loxP) mice, though TG secretion was unaltered (Fig-
ure 2E and Figure S4). Surprisingly, the accumulation of liver
TG in the AFP > Cre;FoxO1(loxP/loxP) mice was suppressed by
concomitant deletion of Akt2 (Figure 2E). Though deletion of
FoxO1 leads to a phenotype opposite to that of deletion of
Akt2, thesedata are inconsistentwith amodel inwhichAkt2 regu-
lates lipid accumulation through suppression of FoxO1 activity.
Akt2 Regulates Hepatic TG Levels Independent
of FoxO1 upon HFD Feeding
Suppression of FoxO1 by shRNA in livers from DIO mice
decreases blood glucose and insulin levels and improves insulinCell Metabolism 14, 5sensitivity as assessed by the euglycemic, hy-
perinsulinemic clamp (Samuel et al., 2006). To
investigate the role of FoxO1 as a downstream
mediator of Akt’s role inmetabolism under path-
ological conditions, we placed the wild-type
controls, AFP > Cre;Akt2(loxP/loxP), AFP > Cre;
FoxO1(loxP/loxP) and AFP > Cre;Akt2(loxP/loxP);
FoxO1(loxP/loxP) mice, on a HFD for 3 months.
Glucose tolerance tests were indistinguishable
in mice of all four genotypes (Figure 3A). Fasting
and fed serum insulin and TG levels were
also similar among these same mice (Figures
3B and 3C). However, under fed conditions,
loss of hepatic Akt2 in HFD-fed mice trended
to a lower TG level in liver, whereas liver TG
upon ablation of FoxO1 did not differ from
wild-type controls (Figure 3D). Deletion ofFoxO1 concomitant with Akt2 did not reverse the protection
from steatosis in AFP > Cre;Akt2(loxP/loxP) mice (Figure 3D), again
militating against the idea that FoxO1 regulates lipid metabolism
downstream of Akt2.
Loss of Akt2 Decreases Hepatic TG Levels in FoxO1
Knockout Mice after Aurothioglucose Treatment
In DIO, deletion of Akt2 in liver reduces hepatic TG without
altering lipogenesis, whereas in ob/ob mice protection from
steatosis is accompanied by a concomitant reduction in lipogen-
esis and lipogenic gene expression (Leavens et al., 2009). To
study the AFP > Cre;Akt2(loxP/loxP);FoxO1(loxP/loxP) mice under
conditions that mimic ob/ob mice, we injected mice with auro-
thioglucose (goldthioglucose, GTG), which causes hypothalamic
damage, hyperphagia, and weight gain (Brecher et al., 1965;
Marshall and Mayer, 1954). As shown in Figure 4A, 8 weeks after
GTG injection, mice of all genotypes displayed significantly
increased body weight and hepatic TG levels compared to
age-matched controls (compare Figure 4B to Figure 2E). AFP >
Cre;Akt2(loxP/loxP) mice trended to lower hepatic TG, while AFP >
Cre;FoxO1(loxP/loxP) mice had significantly elevated TG in liver
(Figure 4B). Interestingly, concomitant deletion of Akt2 and16–527, October 5, 2011 ª2011 Elsevier Inc. 519
Figure 4. Loss of Hepatic Akt2 Decreases TG Accumulation in Liver
Independent of FoxO1 after Aurothioglucose Treatment
(A) Mice with aurothioglucose (GTG) injection gained more weight than age-
matched not-treated (NT) controls. Male mice were fasted overnight and then
injected with 0.3 g/kg bodyweight GTG at 4–5 weeks old, and were maintained
on normal chow for 8 weeks before analysis; n = 4–8 for each genotype; *p <
0.05 by two-way ANOVA followed by Bonferroni’s post test.
(B) Hepatic TG levels under fed conditions in mice injected with GTG as
described above, n = 6–10 for each group. *p < 0.05, **p < 0.01 by one-way
ANOVA followed by Tukey’s post test; error bars represent SEM. Abbrevia-
tions are as indicated in Figure 2.
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to those in AFP > Cre;Akt2(loxP/loxP) rather than AFP > Cre;
FoxO1(loxP/loxP) mice (Figure 4B). This showed that the Akt2
mutant phenotype was dominant to that of FoxO1, which, again,
did not support Akt2 as upstream of FoxO1, but rather sug-
gested that Akt2 regulates hepatic TG levels downstream of or
in parallel to FoxO1.
Akt2 Is Required for Postprandial De Novo Lipogenesis
In order to address the pathways downstream of Akt2 that
mediate lipid homeostasis, we sought to establish a model
more physiological than hypothalamic obesity that would test
the dependency of hepatic lipogenesis on Akt2. To accomplish
this, mice were fasted overnight and then refed a lipogenic
high-carbohydrate diet (HCD). As expected, blood glucose and
serum insulin levels increased by 1.5 hr after HCD refeeding
and remained high through the 12 hr animals were allowed
continuous access to food (Figures 5A and 5B). Deletion of
Akt2 in mouse liver did not alter the glucose or insulin levels
compared to wild-type controls, indicating the minimal require-
ment for hepatic Akt2 in control of postprandial carbohydrate
metabolism (Figures 5A and 5B). Liver weights normalized to
body weight also increased significantly after 6 hr refeeding in
wild-type mice, but this was blunted in AFP > Cre;Akt2(loxP/loxP)
mice (Figure 5C). To evaluate the rate of de novo lipogenesis
under these conditions, we injected D2O at the third hour after
feeding and analyzed the incorporation of D2O into liver palmi-
tate 3 hr later, i.e., 6 hr after feeding. During the labeling period,
de novo lipogenesis increased about 5-fold compared to that
during fasting, and this effect was blunted in the livers lacking
Akt2 (Figure 5D). These data point to a discrepancy between
the requirements for Akt2 in hepatic lipogenesis versus glycemia
following a high-carbohydrate meal. Hepatic mRNAs encoding
lipogenic enzymes increased after refeeding a high-carbohy-
drate meal (Figure 5E). Surprisingly, the expression of Srebp1c
and its targets Acly and Acc were only minimally if at all reduced
in AFP > Cre;Akt2(loxP/loxP) mice, though there was a blunting in
the induction of glucokinase (Gck) and Fasn (Figure 5E). HCD520 Cell Metabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Infeeding suppressed insulin-induced gene 2a (INSIG2a) expres-
sion for at least 6 hr independent of the presence of hepatic
Akt2 (Figure 5E).
To test whether unrestrained activity of FoxO1 is the major
factor responsible for the lack of postprandial de novo lipogen-
esis and hepatic weight gain in AFP > Cre;Akt2(loxP/loxP) mice,
we measured fatty acid synthesis in livers from AFP > Cre;
Akt2(loxP/loxP);FoxO1(loxP/loxP) mice. Elimination of FoxO1 in liver
was without effect on the increase in blood glucose evident after
ingestion of a HCD (Figure 6A). However, deletion of FoxO1 in
liver appeared to reverse the prevention in hepatic weight gain
evident in the AFP > Cre;Akt2(loxP/loxP) livers, much like the
suppression of a similar defect in livers lacking IRS1 and IRS2
(Figure 6B) (Dong et al., 2008). Deletion of FoxO1 alone in liver
led to a trend for increased de novo lipogenesis following a
meal, consistent with the increase in hepatic TG under several
conditions (Figures 2E, 4B, and 6C). Unlike liver size, the de-
crease in lipid synthesis in livers lacking Akt2 was not re-
versed by concomitant removal of FoxO1; instead, AFP > Cre;
Akt2(loxP/loxP);FoxO1(loxP/loxP) livers demonstrated rates of de
novo lipogenesis virtually identical to those in AFP > Cre;
Akt2(loxP/loxP) livers (Figure 6C). Delivery by adenovirus of a domi-
nant-negative form of FoxO1 (Nakae et al., 2001) into AFP > Cre;
Akt2(loxP/loxP);FoxA2(loxP/loxP) livers also failed to reverse the
decreased lipogenesis in Akt2 null livers (data not shown). These
data are consistent with those presented above in which Akt2 is
epistatic to FoxO1 regarding the control of liver TG content.
mTORC1 Is Required for De Novo Lipogenesis
in Mouse Liver
We next turned to the question: since FoxO1 and FoxA2 do not
appear to function downstream of Akt2 in lipid homeostasis,
what pathway could mediate Akt2’s effect on lipogenic gene
expression? The most likely answer lies in the recent observa-
tion that in primary hepatocytes, insulin utilizes a pathway
dependent on mTORC1 to stimulate the processing and expres-
sion of SREBP1c, a transcription factor that drives coordinated
lipogenic gene transcription (Azzout-Marniche et al., 2000;
Chakrabarti et al., 2010; Duvel et al., 2010; Fleischmann and Iy-
nedjian, 2000; Li et al., 2010; Porstmann et al., 2008). To test the
requirement for this pathway in vivo, we injected raptor(loxP/loxP)
mice with an adeno-associated virus expressing liver-specific
Cre recombinase (AAV > Cre) or green fluorescent protein
(AAV > GFP), thus generating hepatic raptor knockout mice or
controls. As shown in Figure 7A, raptor protein levels were
substantially reduced in AAV > Cre;raptor(loxP/loxP) mice, and
the phosphorylation of an mTORC1 target, ribosomal protein
S6 (S6), was not detected, as assayed by reactivity with a phos-
phospecific antibody (Figure 7A). Expression of the lipogenic
genes Srebp1c, Fas, Acly, and Gpat were reduced in AAV >
Cre;raptor(loxP/loxP) mice, though Acc and Gck were unchanged
under fed conditions (Figure 7B). Most notably, de novo lipogen-
esis following a high-carbohydrate meal was largely abrogated
in liver from AAV > Cre;raptor(loxP/loxP) mice (Figure 7C).
Having established the critical role of mTORC1 in de novo
lipogenesis, we then asked whether defects in its expression
and posttranslational processing of SREBP1c explained the
disturbed lipid metabolism in AFP > Cre;Akt2(loxP/loxP) mice.
Following a high-carbohydrate meal, there was an increase inc.
Figure 5. Akt2 Is Required for De Novo Lipogenesis after HCD Refeeding
(A) Blood glucose levels after HCD refeeding. Mice were prefed with HCD for 2 days, fasted overnight, and refed with HCD. Blood glucose was measured at the
indicated time points; n = 4–6 for each condition.
(B) Serum insulin levels after HCD refeeding; n = 4–6 for each condition.
(C) Liver weight to body weight ratio after HCD refeeding; n = 4–6 for each condition.
(D) Newly synthesized palmitate. Mice treated as above were injected with 20 ml/g bodyweight D2O 3 hours after HCD refeeding. Six hours after refeeding, mice
were sacrificed and incorporation of D2O into palmitate measured in liver; n = 3–5 for each condition.
(E) Lipogenic gene expression after HCD refeeding. Mice were treated as described in (A); n = 4–6 for each condition. Con, wild-type controls; L-Akt2,
AFP > Cre;Akt2(loxP/loxP); *p < 0.05, **p < 0.01 by two-way ANOVA followed by Bonferroni’s post test; error bars represent SEM.
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lation initiation factor 4E-1A-binding protein 1 (4EBP1), which
reflects activation of mTORC1 by nutrients and insulin. Sur-Cellprisingly, this was unchanged in AFP > Cre;Akt2(loxP/loxP) mice
(Figure 7D). Both the precursor and the processed form of
SREBP1c increased 6 hr after HCD feeding; induction of theseMetabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Inc. 521
Figure 6. Loss of Hepatic Akt2 Decreases De Novo
Lipogenesis Independent of FoxO1
(A) Fasting and refed blood glucose levels. Two-month-old
male mice were placed on HCD for 3 days, fasted over-
night, and refed with HCD for 6 hr. Blood glucose levels
were taken at fasting, 3 hr refeeding, and 6 hr refeeding
time points, n = 5–7 for each genotype, **p < 0.01 by two-
way ANOVA followed by Bonferroni’s post test, error bars
represent SEM.
(B) Liver weight to body weight ratio. Mice were as
described above. Six hours after refeeding, mice were
sacrificed, and body weight and wet liver weight were
determined; n = 5–7 for each condition, *p < 0.05, **p <
0.01 by two-way ANOVA followed by Bonferroni’s post
test, error bars represent SEM.
(C) De novo lipogenesis, n = 4–7 for each genotype, **p <
0.01 by one-way ANOVA followed by Tukey’s post test;
error bars represent SEM. Abbreviations are as indicated
in Figure 2.
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Akt2 Targets Regulate Hepatic Lipid Metabolismproteins was only slightly reduced in AFP > Cre;Akt2(loxP/loxP)
mice (Figure 7E), consistent with the minimal changes in lipo-
genic gene expression under these conditions (Figure 5E). These
results indicated that the defective lipogenesis was unlikely to
be attributed to lack of activation of mTORC1 and SREBP1c.
Moreover, in the absence of Akt2, stimulation of mTORC1 and
SREBP1c are not sufficient to promote de novo lipogenesis
following a high-carbohydrate meal (Figures 5D, 5E, 7D, and 7E).
FoxO1 has been suggested to suppress mTORC1 activity
by several mechanisms, e.g., stimulating the expression of
mTORC1 inhibitors such as Sestrin3, Raptor independent
companion of mTOR (Rictor), and possibly Tuberous sclerosis
complex 1 (TSC1) (Chen et al., 2010; Harvey et al., 2008). To
ask whether such a mechanism accounts for the suppression
of lipid accumulation by FoxO1, we assessed mTORC1 activity
in animals lacking hepatic FoxO1. Six hours after ingesting
a high-carbohydrate meal, hepatic phospho-S6 was not al-
tered in AFP > Cre;FoxO1(loxP/loxP) or AFP > Cre;Akt2(loxP/loxP);
FoxO1(loxP/loxP) mice (Figure 7E). The expression of Srebp1c,
Gck, Fasn, Acc, Acly, and Sestrin3 was also unchanged in livers
from AFP > Cre;FoxO1(loxP/loxP) mice after HCD refeeding (Fig-
ure S5). These data argue against mTORC1 as the mediator of
hepatic TG accumulation induced by deletion of FoxO1.
Insulin-Stimulated Phosphorylation of ATP Citrate
Lyase Is Blunted in Akt2-Deficient Livers
To explore other potential mechanisms utilized by Akt2 to
regulate lipid metabolism, we examined two other pathways
known to modulate hepatic lipogenesis activity responding to
insulin signaling. ATP-citrate lyases (ACLY) catalyze the
cleavage of cytosolic citrate to oxaloacetate and acetyl-CoA,522 Cell Metabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Inc.the latter a precursor for fatty acid synthesis.
The activity of ACLY is regulated transcription-
ally as a target of SREBP1c as well as at the
posttranslational level by Akt and protein kinase
A phosphorylation (Berwick et al., 2002; Horton
et al., 2002; Potapova et al., 2000). Insulin
injection stimulated phosphorylation of Akt
and ACLY, and phosphorylation of both wasblunted in livers from AFP > Cre;Akt2(loxP/loxP) mice (Figure S7A).
To study this in more detail, hepatocytes were isolated from
control and Akt2 KO livers. Again, insulin promoted Akt and
ACLY phosphorylation in a dose-dependent manner. Phosphor-
ylation of both was reduced in primary hepatocytes from
Akt2-deficient livers, particularly at low concentrations of insulin
(Figure S7B). Those data provide an additional pathway poten-
tially dependent on Akt2 for the increase in de novo lipogenesis
in liver.
Atypical PKCs (aPKCs) have been reported to be activated by
insulin and to promote SREBP1c expression in liver (Farese
et al., 2005; Matsumoto et al., 2003; Taniguchi et al., 2006). To
ask whether aPKC is dependent on Akt2, we measured aPKC
phosphorylation and activity in livers from control and AFP >
Cre;Akt2(loxP/loxP) mice but found the levels to be indistinguish-
able (data not shown). However, we were unable to detect
increases in hepatic aPKC phosphorylation or activity following
insulin injection of control or AFP > Cre;Akt2(loxP/loxP) mice
(data not shown).
DISCUSSION
The metabolic disturbances associated with type 2 diabetes
mellitus and the metabolic syndrome have been perceived
as being due to an inability of insulin to promote effectively its
anabolic actions, a condition long referred to as insulin re-
sistance. However, this view has been modified recently with
the increasing appreciation that, while the ‘‘insulin-resistant’’
liver displays some features consistent with an inability of
insulin to act, most notably an inappropriately high glucose
output, its characteristic increased de novo lipogenesis and TG
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insulin sensitivity. The simplest, though by nomeans only, expla-
nation for this phenomenon is that insulin resistance occurs at
a step distal to a bifurcation in insulin signaling, resulting in selec-
tive inhibition of the hormone’s effect on glucose output, while
permitting signaling to lipid metabolism. Work from our labora-
tory as well as others suggests that this divergence occurs
downstream of Akt, and thus the identification of the specific
pathways that Akt2 utilizes to regulate metabolism has achieved
particular importance (He et al., 2010; Leavens et al., 2009). In
this study, we investigated the roles of two proposed Akt target
transcription factors, FoxO1 and FoxA2, and an indirect route for
control of a third, SREBP1c, which is regulated bymTORC1. Our
data show that, whereas suppression of FoxO1 activity is down-
stream of Akt in the inhibition of hepatic glucose output, phos-
phorylation of neither FoxO1 nor FoxA2 is likely to mediate
insulin’s effects on de novo lipogenesis and TG accumulation
in liver. Our data also support the notion that mTORC1 is
required for maintenance of Srebp1c expression and de novo
lipogenesis, but its activation is not sufficient to reverse the
reduction of de novo lipogenesis coincident with deletion of
Akt2. Moreover, it is likely that the mechanism by which Akt2
induces lipogenesis after a high-carbohydrate meal is not based
on regulation of gene expression by any of the three transcription
factors assessed in this study.
Considerable data support a role for FoxO1 in the control of
hepatic gluconeogenic genes expression, though there is
much less clarity regarding its importance for glycemia and
hepatic lipid metabolism. As has been reported, we found that
under normal conditions, hepatic deletion of FoxO1 resulted in
an impaired pyruvate tolerance test, in this study independent
of Akt2 (Figures 2B and 2C) (Matsumoto et al., 2007). Inhibition
of FoxO1 activity by various techniques in genetically obese
and DIO mouse models decreases blood glucose and insulin
levels, and reduces hepatic glucose production as assayed by
hyperinsulinemic-euglycemic clamp; loss of hepatic FoxO1
ameliorates fasting hyperglycemia in the STZ-induced diabetic
mice (Altomonte et al., 2003; Haeusler et al., 2010a; Kamagate
et al., 2008; Nakae et al., 2002; Samuel et al., 2006). These
studies suggest that FoxO1 activity contributes significantly to
insulin resistance under pathological conditions. However, in
our studies, AFP > Cre;FoxO1(loxP/loxP)mice did not demonstrate
reduced blood glucose and insulin levels during DIO, perhaps
due to the diet employed and/or the mouse strain used (Figures
3A and 3B).
We also found that livers deficient in FoxO1 trended to
increased hepatic TG content, as was reported previously after
siRNA-mediated knockdown of FoxO1 or ablation of three
FoxO isoforms in liver; these data suggest that FoxO1 normally
suppresses lipid accumulation in liver (Kamagate et al., 2008;
Tao et al., 2011). Nonetheless, the action of Akt2 to promote
hepatic lipid accumulation is not mediated by a suppression of
FoxO1, as concomitant deletion of both genes leads to a pheno-
type resembling loss of Akt2 alone (Figures 2E, 4B, and 6C).
Rather, FoxO1 signals to TG content by a pathway genetically
upstream of or parallel to Akt2. FoxO1 regulates hepatic lipid
content during fasting by accelerating TG secretion through
increases in MTP (Kamagate et al., 2008). However, others
have suggested FoxO1 inhibits VLDL-TG secretion in patholog-Cellical conditions (Dong et al., 2008; Haeusler et al., 2010a; Matsu-
moto et al., 2007; Zhang et al., 2006). Fasting hepatic and serum
TG levels were not changed in AFP > Cre;FoxO1(loxP/loxP) mice
under normal conditions in this study and others (Figure 2D
and Figure S3C) (Matsumoto et al., 2007), and no change was
found on the rate of TG secretion in AFP > Cre;FoxO1(loxP/loxP)
mice (Figure S4). There were no alterations in AFP > Cre;
FoxO1(loxP/loxP) mice of serum TG under obese conditions, and
MTP expression was not changed in AFP > Cre;FoxO1(loxP/loxP)
mice during hypothalamic obesity (Figure 3 and Figure S6).
These data suggest that changes in TG secretion are not respon-
sible for hepatic TG accumulation in AFP > Cre;FoxO1(loxP/loxP)
mice. FoxO1 also modulates mTORC1 activity, which regulates
Srebp1c levels and lipogenesis (Chen et al., 2010; Duvel et al.,
2010; Harvey et al., 2008). However, deletion of Akt2, FoxO1,
or both did not alter phosphorylation of ribosomal protein S6
after HCD refeeding (Figure 7E), suggesting that the pathway
by which FoxO1 normally suppresses lipid accumulation is
independent of mTORC1.
FoxA2 has been reported to stimulate fatty acid oxidation,
increase TG secretion, and reduce hepatic TG accumulation in
obese animals (Wolfrum et al., 2004, 2008; Wolfrum and Stoffel,
2006). Much of the data supporting this model are derived from
experiments involving expression of constitutively active FoxA2
in mouse liver, and thus have the potential of off-target effects.
Other experiments took advantage of the reduction in nuclear
FoxA2 associated with the obese state, during which the liver
is likely to have numerous uncharacterized, complicating meta-
bolic alterations. However, other studies found no change to
the nuclear localization of FoxA2, even in the extreme case of
elevated insulin levels in ob/ob mice (Zhang et al., 2005). In
loss-of-function studies, liver-specific FoxA2 knockout mice
displayed no abnormality in hepatic TG levels, consistent with
the current results (Bochkis et al., 2008). Under normal chow
feeding or in mice with DIO, loss of hepatic FoxA2 did not affect
serum glucose and insulin or hepatic TG levels (Figures 1B and
1C and Figures S1 and S2). These data are compatible with
a model in which inhibition of FoxA2 is not required for Akt2 to
regulate hepatic TG accumulation. These results are qualified
by the possibility that, in other mouse strains, the requirements
for hepatic steatosis might be different.
Recently, mTORC1 has been shown to enhance de novo lipo-
genesis by regulating Srebp1c expression and processing
(Chakrabarti et al., 2010; Duvel et al., 2010; Li et al., 2010; Porst-
mann et al., 2008). The full activation of mTORC1 requires both
nutrients and growth factor signaling, which determine cellular
location and Akt-dependent activation of the mTORC1 complex,
respectively (Sancak et al., 2008, 2010; Sengupta et al., 2010b).
In tissue culture cells and primary hepatocytes, insulin/Akt regu-
lates SREBP1c expression and processing and de novo lipogen-
esis in an mTORC1-dependent manner (Azzout-Marniche et al.,
2000; Chakrabarti et al., 2010; Duvel et al., 2010; Fleischmann
and Iynedjian, 2000; Li et al., 2010; Porstmann et al., 2008).
However, the model of an obligate role for mTORC1 in hepatic
lipogenesis has not been tested genetically in vivo. Herein we
report that conditional deletion of raptor in liver abolished
mTORC1 activity, leading to a reduction in the expression of
Srebp1c and its targets and decreased de novo lipogenesis (Fig-
ures 7A–7C). Interestingly, even though AFP > Cre;Akt2(loxP/loxP)Metabolism 14, 516–527, October 5, 2011 ª2011 Elsevier Inc. 523
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cantly decreased de novo lipogenesis following a high-carbohy-
drate meal, activation of mTORC1 and SREBP1c were largely
unaffected (Figures 5D, 7D, and 7E). These data indicate that
mTORC1 activation is not sufficient to induce lipogenesis under
these conditions. During the revision of this paper, Yecies et al.
reported an mTORC1-independent pathway by which Akt2
signals through INSIG2a to promote SREBP1c processing (Ye-
cies et al., 2011). We found no change in the normal decrease
in hepatic INSIG2a mRNA in AFP > Cre;Akt2(loxP/loxP) mice after
HCD refeeding and only a modest reduction in the nuclear
form of SREBP1c or expression of its target genes (Figures 5E
and 7E). Thus, the mTORC1-independent pathway revealed in
this study by liver-specific deletion of Akt2 does not represent
induction of INSIG2a and is unlikely to be related to SREBP1c
processing or expression. Rather, we propose that the require-
ment for Akt2 is linked to its role in the posttranslational control
of other targets such as ACLY.
Taking these data in aggregate, we suggest that Akt2 pro-
motes hepatic lipid accumulation and de novo lipogenesis inde-
pendent of FoxA2 and FoxO1. Moreover, activated mTORC1
and SREBP1c and increased lipogenic gene expression is
required but not sufficient for postprandial lipogenesis. Thus,
our data provide strong support for the notion that nutrients
have a direct role in the liver to promote anabolic lipid metabo-
lism by a process dependent on the presence of a functional
mTORC1 complex as well as other Akt-dependent signaling
pathways.
EXPERIMENTAL PROCEDURES
Animals
The AFP > Cre;Akt2(loxP/loxP), AFP > Cre;FoxO1(loxP/loxP), and RaptorloxP/loxP
mice have been described previously (Leavens et al., 2009; Matsumoto
et al., 2007; Sengupta et al., 2010a; Zhang et al., 2005). All animals were raised
and treated with approval from the University of Pennsylvania IACUC in accor-
dance with National Institutes of Health (NIH) guidelines. Mice were of a 129/
FVB/C57BL6 mixed background, and male littermates were used for all
studies. In the FoxA2 experiments, the wild-type control group included
mice of genotypes AFP > CRE;Akt2loxP/+; FoxA2loxP/+; and Akt2loxP/LoxP;
FoxA2loxP/loxP. Mice labeled asAFP >Cre;Akt2(loxP/loxP) included the genotypes
AFP > Cre;Akt2loxP/loxP; FoxA2loxP/+ and AFP > Cre;Akt2loxP/loxP; FoxA2+/+.
Mice labeled as AFP > Cre;FoxA2(loxP/loxP) included the genotypes AFP > Cre;
Akt2loxP/+; FoxA2loxP/loxP and AFP > Cre;Akt2+/+; FoxA2loxP/loxP. In the FoxO1
experiments, wild-type controls include genotypes AFP > Cre;Akt2loxP/+;
FoxO1loxP/+ and Akt2loxP/LoxP; FoxO1loxP/loxP. Mice indicated as AFP > Cre;
Akt2(loxP/loxP) included the genotypes AFP > Cre;Akt2loxP/loxP; FoxO1loxP/+ and
AFP > Cre;Akt2loxP/loxP; FoxO1+/+. Mice labeled as AFP > Cre;FoxO1(loxP/loxP)
included the genotypes AFP > Cre;Akt2loxP/+; FoxO1loxP/loxP and AFP > Cre;
Akt2+/+; FoxO1loxP/loxP. In all cases there were no metabolic phenotypes
among the pooled genotypes including Cre expressed alone. Mice were main-Figure 7. Raptor Is Required for Lipogenic Gene Expression and De N
(A) Western blot of Raptor knockout livers. RaptorloxP/loxP male mice were mai
AAV-TBG-Cre (AAV > Cre;raptor(loxP/loxP); A-CRE) at 6 weeks of age. Two weeks
normal chow for 4 hr (refed) before sacrifice.
(B) Lipogenic gene expression under fed conditions; n = 6–7 for each condition,
(C) De novo lipogenesis, n = 6–7 for each condition, **p < 0.01 by Student’s t tes
(D) Western blot for liver samples from wild-type controls and AFP > Cre;Akt2(lox
(E) Western blot for full-length SREBP1 (flSREBP1) and processed SREBP1 (nSR
Cre;Akt2(loxP/loxP) mice were used for blotting full-length SREBP1 and processed
(F) Western blot for liver samples from wild-type controls (CON), AFP > Cre;
Akt2(loxP/loxP);FoxO1(loxP/loxP) (L-Akt2:FoxO1) mice 6 hr after HCD refeeding. Mice
Celltained on a normal chow diet (laboratory rodent diet 5001, LabDiet) unless
otherwise noted under 12 hr light/dark cycle (7 a.m./7 p.m.) in a barrier facility.
When fed with HFD (D12331i, Research Diets), mice were started at an age of
1 month and remained for 3 months.
For aurothioglucose (GTG, A0606, Sigma Aldrich) treatment, mice were
maintained on normal chow. At 5–6 weeks old, mice were fasted for 24 hr
and then injected intraperitoneally (i.p.) with one dose of 0.3 g/kg GTG in
PBS. After injection, mice were kept fasted for another 20 hr before normal
chow diet was freely accessible for the following 2 months. This protocol
has been suggested to reduce mortality caused by GTG injection in mice
(Brecher et al., 1965).
For acute excision of Raptor in liver, the adeno-associated virus was
generated by Viral Vector Core at University of Pennsylvania. GFP or Cre
reconbimase was driven by a liver-specific promoter, thyroxine-binding
globulin (TBG) promoter. Mice were injected postorbitally at a dosage of
1.03 1011gc virus diluted in PBS at 6 weeks of age and maintained on normal
chow for another 2 weeks before analysis.
Metabolic Measurement
Blood glucose, serum insulin, and hepatic and serum TG levels weremeasured
as described before (Leavens et al., 2009). For experiments involving fasting,
mice were deprived of food overnight. For ‘‘fed’’ measurements, mice were
reared on designated diet ad libitum before blood and liver samples were taken
during the morning between 8 and 10 a.m. For glucose and pyruvate tolerance
test, mice were fasted overnight followed by i.p. injection of 2 g/kg glucose or
pyruvate, and then blood glucose levels were taken at designated time points.
De Novo Lipogenesis
For de novo lipogenesis assay, mice were fed with HCD (D12450B, Research
Diets) for 2 days, and then treated as described in the text. Whole blood and
liver samples were taken 3 hr after D2O injection and frozen in liquid nitrogen.
Palmitate was isolated and analyzed by using gas chromatography-electron
impact ionization mass spectrometry by the Stable Isotope Tracer Kinetic
Service Center in the Institute of Diabetes, Obesity, and Metabolism, Univer-
sity of Pennsylvania. The absolute amount of newly made palmitate was
assumed equivalent to the de novo lipogenesis rate.
TG Secretion Assay
TG secretion assay was performed as described previously (Millar et al., 2005).
Mice were fasted overnight and then injected i.p. with 1 g/kg poloxamer 407
(kindly provided by Dr. John S. Millar, University of Pennsylvania). Blood
samples were collected at indicated time points and assayed for serum TG.
Statistics
All data are presented as mean ±SEM. As noted in the figure legends, data
were analyzed by using unpaired Student’s t test with two-tailed analysis,
one-way ANOVA followed by Tukey’s post test, or two-way ANOVA followed
by Bonferroni’s post test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.09.001.ovo Lipogenesis
ntained on normal chow and injected with either AAV-TBG-GFP (A-GFP) or
after virus injection, mice were fasted overnight (fasted) and then refed with
*p < 0.05; **p < 0.01 by Student’s t test; error bars represent SEM.
t; error bars represent SEM.
P/loxP) mice after HCD refeeding. Mice were treated as described in Figure 5.
EBP1). Liver samples from 24 hr fasted or 6 hr HCD refeeding control or AFP >
SREBP1.
Akt2(loxP/loxP) (L-Akt2), AFP > Cre;FoxO1(loxP/loxP) (L-FoxO1), and AFP > Cre;
were treated as described in Figure 6C.
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